1
|
Xu R, Ji X, Pei X, Yu Y. Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma. Am J Transl Res 2023; 15:1117-1128. [PMID: 36915764 PMCID: PMC10006802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 12/26/2022] [Indexed: 03/16/2023]
Abstract
OBJECTIVE To compare the clinical effect and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate-advanced hepatocellular carcinoma. METHODS In this retrospective study, 84 patients with intermediate-advanced hepatocellular carcinoma admitted to the First Affiliated Hospital of Anhui Medical University and the First Affiliated Hospital of USTC from June 2019 to June 2021 were enrolled. The control group was given TACE combined with sorafenib, and the experimental group was given TACE combined with lenvatinib. The clinical efficacy, tumor markers, liver function indexes, and occurrence of toxic and side effects were compared between the two groups. RESULTS The disease control rate (DCR) and the objective remission rate (ORR) of the experimental group was higher than that of the control group, and the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in the levels of alpha fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP) between the two groups (both P>0.05); after the treatment, the levels of AFP and DCP in both groups decreased, and those in the experimental group were lower than the control group (all P<0.05). Before treatment, there were no significant differences in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or lactate dehydrogenase (LDH), bilirubin (BIL) between the two groups (all P>0.05); after treatment, the levels of ALT, AST and LDH, BIL in both groups decreased, with the experimental group lower than the control group (all P<0.05). The overall survival (OS) and progression-free survival (PFS) in the experimental group were significantly higher than in the control group (both P<0.05). The incidences of symptoms of diarrhea, hand-foot syndrome, hypertension and rash in the experimental group were higher than those in the control group (all P<0.05). Fatigue, digestive tract reaction, bone marrow suppression and abnormal liver function of the two groups were similar (all P>0.05). CONCLUSION Compared with TACE plus sorafenib, TACE plus lenvatinib can better control disease progression, reduce the levels of tumor markers, and stabilize the liver function of patients with intermediate-advanced hepatocellular carcinoma.
Collapse
Affiliation(s)
- Rui Xu
- Department of Radiology, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China
| | - Xuebing Ji
- Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230036, Anhui, China
| | - Xiaohong Pei
- Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230036, Anhui, China
| | - Yongqiang Yu
- Department of Radiology, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China
| |
Collapse
|
2
|
Takaki K, Nakano M, Fukumori K, Yano Y, Zaizen Y, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Torimura T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. J Clin Med 2022; 11:jcm11061483. [PMID: 35329809 PMCID: PMC8953328 DOI: 10.3390/jcm11061483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/03/2022] [Accepted: 03/07/2022] [Indexed: 12/24/2022] Open
Abstract
Chemolipiodolization (CL) is less invasive than transarterial chemoembolization (TACE) for managing hepatocellular carcinoma (HCC) because it helps avoid embolization. However, the treatment outcomes of percutaneous radiofrequency ablation (PRFA) with or without CL for HCC remain unclear. Herein, we compared the prognostic factors for overall survival (OS) following PRFA with or without CL for HCC using propensity-score-matched analysis. A total of 221 patients with HCC treated with PRFA at Saga Central Hospital between April 2004 and October 2020, with or without CL, were enrolled. No significant difference was observed in OS between PRFA with and without CL cohorts (median survival time (MST): 4.5 vs. 5.4 years; p = 0.0806). To reduce the confounding effects of 12 variables, we performed propensity-score-matched analysis to match patients treated with PRFA with or without CL. No significant difference was observed in OS between PRFA with and without CL cohorts (MST: 4.0 vs. 3.6 years; p = 0.5474). After stratification according to tumor size, no significant difference was observed in OS for patients with tumor size ≥20 mm between PRFA with and without CL cohorts (MST: 3.5 vs. 3.4 years; p = 0.8236). PRFA with CL was not a significant prognostic factor in both univariate and multivariate analyses (p = 0.5477 and 0.9600, respectively). Our findings suggest that PRFA with CL does not demonstrate more favorable prognosis than PRFA without CL for HCC, regardless of tumor size.
Collapse
Affiliation(s)
- Kota Takaki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
- Division of Gastroenterology, Department of Medicine, Japan Community Health Care Organization, Saga Central Hospital, Saga 849-8522, Japan;
| | - Masahito Nakano
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
- Division of Gastroenterology, Department of Medicine, Japan Community Health Care Organization, Saga Central Hospital, Saga 849-8522, Japan;
- Correspondence: ; Tel.: +81-942-35-3311; Fax: +81-942-34-2623
| | - Kazuta Fukumori
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
- Division of Gastroenterology, Department of Medicine, Omuta City Hospital, Omuta 836-8567, Japan
| | - Yoichi Yano
- Division of Gastroenterology, Department of Medicine, Japan Community Health Care Organization, Saga Central Hospital, Saga 849-8522, Japan;
| | - Yuki Zaizen
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
- Division of Gastroenterology, Department of Medicine, Japan Community Health Care Organization, Saga Central Hospital, Saga 849-8522, Japan;
| | - Takashi Niizeki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Kotaro Kuwaki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Masaru Fukahori
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Takahiko Sakaue
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Sohei Yoshimura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Mika Nakazaki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| | - Takuji Torimura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (K.T.); (K.F.); (Y.Z.); (T.N.); (K.K.); (M.F.); (T.S.); (S.Y.); (M.N.); (T.T.)
| |
Collapse
|
3
|
Shi F, Wu M, Lian SS, Mo ZQ, Gou Q, Xu RD, Li HL, Huang ZM, Wu PH, Chen XM. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes. Radiology 2019; 293:707-715. [PMID: 31638492 DOI: 10.1148/radiol.2019181991] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background Transarterial chemoembolization (TACE) is an effective downstaging procedure for hepatocellular carcinoma (HCC). However, knowledge of the effectiveness of radiofrequency ablation (RFA) after downstaging of HCC is currently lacking. Purpose To evaluate the clinical outcomes of RFA after downstaging of HCC by using TACE. Materials and Methods This retrospective study investigated a cohort of patients who underwent RFA with curative intent after downstaging with TACE to meet Milan criteria (one lesion up to 5 cm or no more than three lesions ≤3 cm without vascular invasion or extrahepatic metastasis) from January 2012 to July 2017. A control group of patients initially meeting the Milan criteria also underwent RFA as first-line treatment in the same period. Overall survival (OS), disease-free survival (DFS), and major complication rates were compared by using the log-rank test. To reduce potential bias, a propensity score analysis was also performed. Results There were 72 patients (median age, 56.5 years; range, 30-78 years; 67 men) in the downstaging group and 357 patients meeting the Milan criteria (median age, 58.0 years; range, 25-87 years; 313 men) included in this study. After propensity score matching, the 1-, 3-, and 5-year OS rates were 99%, 80%, and 66%, respectively, for the patients in the downstaging group and 94%, 84%, and 69%, respectively, for the patients in the Milan criteria group. The 1-, 3-, and 5-year DFS rate were 73%, 34%, and 24% for the downstaging group and 74%, 43%, and 37% for the Milan criteria group. There were no differences in the OS, DFS, or major complication rates between the two groups (P = .74, P = .39, P = .73, respectively). Conclusion The long-term patient survival and major complication rates of radiofrequency ablation following transarterial chemoembolization downstaging for hepatocellular carcinoma were similar to that of patients initially meeting the Milan criteria. © RSNA, 2019 See also the editorial by vanSonnenberg and Mueller in this issue.
Collapse
Affiliation(s)
- Feng Shi
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Ming Wu
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Shan-Shan Lian
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Zhi-Qiang Mo
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Qing Gou
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Rong-De Xu
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Hui-Lan Li
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Zhi-Mei Huang
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Pei-Hong Wu
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| | - Xiao-Ming Chen
- From the Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Second Rd, Guangzhou, Guangdong 510080, China (F.S., Z.Q.M., Q.G., R.D.X., X.M.C.); Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, China (M.W.); Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (S.S.L., H.L.L.); and Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China (Z.M.H., P.H.W.)
| |
Collapse
|
4
|
Endo K, Kuroda H, Oikawa T, Okada Y, Fujiwara Y, Abe T, Sato H, Sawara K, Takikawa Y. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53:1575-1583. [PMID: 30577723 DOI: 10.1080/00365521.2018.1548645] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVES Transcatheter arterial chemoembolization (TACE) is the standard therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). This study aimed to determine whether combination therapy with radiofrequency ablation (RFA) and TACE was superior to TACE monotherapy for intermediate-stage HCC and identify cases in which this technique was the most effective. MATERIALS AND METHODS We selected patients with intermediate HCC who met the following eligibility criteria: (1) ≥ 20 years of age, (2) receiving initial therapy, (3) ≤7 tumors, and (4) maximum tumor diameter <5 cm. We performed propensity score matching (PSM) using potential confounding factors. We retrospectively compared the cumulative overall survival rate and recurrence-free survival rate between the TACE + RFA and TACE groups. Additionally, a sub-group analysis was performed for preoperative factors. RESULTS Among the 103 patients, 92 were selected using PSM. The cumulative overall survival rates at 1, 3, and 5 years for the TACE + RFA group were 97.4%, 70.4%, and 60.4%, respectively, which were significantly higher than those for the TACE group (92.7%, 55.7%, and 22.8%, respectively, p = .045). The recurrence-free survival rates at 0.5, 1, and 2 years for the TACE + RFA group were 80.0%, 58.6%, and 33.3%, respectively, which were significantly higher than those for the TACE group (34.5%, 8.8%, and 2.9%, respectively, p < .01). For the sub-group with α-fetoprotein (AFP) <100 ng/mL, the TACE + RFA group demonstrated a significantly improved prognosis than the TACE group (p = .036). CONCLUSIONS The addition of RFA to TACE improved cumulative overall and recurrence-free survival in patients with intermediate-stage HCC, especially in patients with AFP <100.
Collapse
Affiliation(s)
- Kei Endo
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Hidekatsu Kuroda
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Takayoshi Oikawa
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Yohei Okada
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Yudai Fujiwara
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Tamami Abe
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Hiroki Sato
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Kei Sawara
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| | - Yasuhiro Takikawa
- a Division of Hepatology, Department of Internal Medicine , Iwate Medical University School of Medicine , Morioka , Japan
| |
Collapse
|
5
|
Dong L, Zhang X, Xiang W, Ni J, Zhou W, Li H. Post-transcription mediated Snail stabilization is involved in radiation exposure induced invasion and migration of hepatocarcinoma cells. Biomed Pharmacother 2018; 103:767-772. [PMID: 29684855 DOI: 10.1016/j.biopha.2018.04.095] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 03/23/2018] [Accepted: 04/13/2018] [Indexed: 02/07/2023] Open
Abstract
Increasing evidences suggested that radiotherapy can paradoxically promote tumor invasion and metastatic processes, while its detailed mechanism is not well illustrated. Our present study found that radiation can promote the migration and invasion of hepatocellular carcinoma (HCC) cells via induction of epithelial mesenchymal transition (EMT), which was evidenced by the results that radiation induced up regulation of vimentin while down regulation of E-Cadherin. As to the EMT-related transcription factors, radiation increased the expression of Snail, while not Slug, ZEB1 or TWIST. This was confirmed by the results that radiation increased the nuclear translocation of Snail in HCC cells. However, radiation had no effect on the expression or half-life of Snail mRNA. In HCC cells treated by cycloheximide (CHX, the translation inhibitor), radiation significantly increased the half-life of Snail protein, which suggested that radiation increased the expression of Snail via up regulation of its protein stability. Radiation increased the expression of COP9 signalosome 2 (CSN2), which has been reported to block the ubiquitination and degradation of Snail. Silence of CSN2/Snail can attenuate radiation induced cell migration and EMT of HCC cells. Collectively, our data suggested that radiation can promote HCC cell invasion and EMT by stabilization of Snail via CSN2 signals.
Collapse
Affiliation(s)
- Liyang Dong
- Departments of Invasive Technology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China
| | - Xuebang Zhang
- Departments of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China
| | - Wei Xiang
- Departments of Invasive Technology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China
| | - Junwei Ni
- Departments of Invasive Technology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China
| | - Weizhong Zhou
- Departments of Invasive Technology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China
| | - Haiyan Li
- Departments of Rehabilitation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
| |
Collapse
|
6
|
Wang H, Liu B, Long H, Zhang F, Wang S, Li F. Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Lett 2017; 14:2699-2702. [PMID: 28927032 PMCID: PMC5588120 DOI: 10.3892/ol.2017.6483] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 05/05/2017] [Indexed: 12/23/2022] Open
Abstract
We studied the clinical effects of percutaneous radiofrequency ablation (RFCA) combined with trans-catheter arterial chemoembolization (TACE) in the treatment of breast cancer with liver metastasis. Eighty-eight patients with a diagnosis of breast cancer with liver metastasis for the first time and patients with liver metastasis after radical mastectomy were consecutively selected. The subjects were divided according to the different treatment methods. They were divided either into the control group of 50 cases or the observation group of 38 cases. Breast cancer patients underwent radical mastectomy with conventional systemic venous chemotherapy. The liver metastasis control group used TACE, while the observation group combined RFCA with TACE. The two groups were followed up for a median time of 20 months, and the clinical effects were compared. The effective rate of the observation group was higher than that of the control group; differences were statistically significant (P<0.05). There was no differences in the incidence of complications between the two groups (P>0.05). The progression free survival, median survival time and survival rate of the observation group were increased; differences were statistically significant (P<0.05). Therefore, RFCA combined with TACE in the treatment of breast cancer with liver metastasis is safe and effective.
Collapse
Affiliation(s)
- Haijun Wang
- Department of General Surgery, Anqiu Hospital of Chinese Traditional Medicine, Anqiu, Shandong 262100, P.R. China
| | - Bin Liu
- Department of Thyroid and Breast Surgery, Tengzhou Central People's Hospital, Tengzhou, Shandong 277500, P.R. China
| | - Houlong Long
- Department of Thyroid and Breast Surgery, Tengzhou Central People's Hospital, Tengzhou, Shandong 277500, P.R. China
| | - Fengfeng Zhang
- Department of Thyroid and Breast Surgery, Tengzhou Central People's Hospital, Tengzhou, Shandong 277500, P.R. China
| | - Silei Wang
- Department of Thyroid and Breast Surgery, Tengzhou Central People's Hospital, Tengzhou, Shandong 277500, P.R. China
| | - Feng Li
- Department of Thyroid and Breast Surgery, Tengzhou Central People's Hospital, Tengzhou, Shandong 277500, P.R. China
| |
Collapse
|